Syn-Coll Limited Evidence

What It Is

Syn-Coll is a lipopeptide consisting of the tripeptide sequence L-Lysine–L-Valine–L-Lysine N-terminally conjugated to palmitic acid (hexadecanoic acid). Its INCI name is Palmitoyl Tripeptide-5; older labels occasionally list it as "Palmitoyl Tripeptide-3" after an earlier INCI numbering that the International Nomenclature of Cosmetic Ingredients reassigned. The molecular formula is C₃₃H₆₅N₅O₅ and the molecular weight is approximately 611.9 Da. The palmitoyl group is what converts an otherwise hydrophilic, barrier-excluded tripeptide into a lipophilic anchor capable of partitioning into the stratum corneum and reaching live epidermis and upper dermis on topical application. The raw peptide itself (Lys-Val-Lys, tripeptide-5) is unremarkable in cosmetic assays; the commercial ingredient is always the palmitoylated form.

Syn-Coll was developed and commercialized by Pentapharm Ltd. (Basel, Switzerland), a longtime supplier of active cosmetic ingredients. Pentapharm was acquired by DSM Nutritional Products in 2007, and the Syn-Coll trademark now sits in DSM's Personal Care portfolio. The commercial product is typically supplied as a preservative-free aqueous solution containing roughly 100–200 ppm of the active peptide and intended to be used at 2–4% of the finished formula (depending on claim structure and supplier documentation). At those use levels the final in-product concentration of active palmitoyl tripeptide-5 is on the order of 40–80 parts per million — single-digit micrograms of peptide per gram of product.

The compound is used exclusively topically. It is not a research peptide intended for systemic administration by any route, and there is no published pharmacokinetic or safety data supporting subcutaneous, intramuscular, intravenous, intranasal, or oral use. Unlike peptides such as BPC-157, GHK-Cu (in its systemic context), or GHRP-class compounds, Syn-Coll has no legitimate "research chemical" systemic application — it is a cosmetic signal molecule from inception. Any vendor offering Syn-Coll for injection is selling a topical ingredient out of its intended regulatory class.

Regulatory classification places Syn-Coll firmly in the cosmetic-ingredient universe, not the drug universe. In the United States it is a permitted cosmetic ingredient under the FD&C Act definition of a cosmetic (articles intended for cleansing, beautifying, or altering appearance), and in the European Union it is listed in the CosIng database of cosmetic ingredients. Neither jurisdiction has approved it as a drug for any indication, and cosmetic-labeling rules prohibit claims that it "treats," "cures," or "prevents" any disease or structurally alters the skin in a way that would trigger drug classification.

The clinical evidence base for Syn-Coll — as distinct from the evidence base for the underlying TSP-1/TGF-β activation biology — is limited and substantially manufacturer-sponsored. PubMed does not index independent randomized controlled trials of Syn-Coll as a monotherapy against vehicle using rigorous wrinkle-morphometry endpoints. The strongest evidence in the peer-reviewed cosmetic-science literature is narrative review-chapter coverage; the strongest individual data points are supplier-issued technical bulletins and conference abstracts. This is typical of the cosmetic active-ingredient category, but it is an important honest framing for a site that reviews peptides by evidence quality.

Mechanism of Action

Syn-Coll's mechanistic story is a direct structural borrowing from one of the best-characterized non-proteolytic activation pathways in extracellular matrix biology: thrombospondin-1–dependent activation of latent TGF-β. The underlying pathway is rigorous; what is claimed for the tripeptide is a minimalist mimicry of one step of that pathway, and the quality of the claim depends on how completely the tripeptide reproduces the natural sequence's activity. Key mechanistic points:

• Latent TGF-β biology — TGF-β1 is secreted by fibroblasts, platelets, and many other cell types as a latent precursor. In the small latent complex (SLC), the mature active TGF-β dimer is non-covalently bound to its own propeptide, the latency-associated peptide (LAP), which shields the receptor-binding surface. In the large latent complex (LLC), the SLC is additionally tethered to the extracellular matrix through LTBP (latent TGF-β binding protein). For TGF-β to signal, the mature domain must be released from LAP — a step that is tightly regulated because unchecked TGF-β signaling drives fibrosis and scarring (Murphy-Ullrich & Poczatek, 2000; Murphy-Ullrich & Suto, 2018).
• TSP-1 as a latent-TGF-β activator — Thrombospondin-1 is a 450-kDa homotrimeric matricellular glycoprotein stored in platelet α-granules and deposited into the extracellular matrix. Schultz-Cherry and Murphy-Ullrich (1993, J Cell Biol; PMID 8349738) first showed that TSP-1 stripped of co-associated TGF-β can non-proteolytically activate latent TGF-β secreted by endothelial cells. Crawford et al. (1998, Cell; PMID 9657149) then demonstrated in TSP-1-null mice that TSP-1 is responsible for a physiologically significant fraction of latent TGF-β1 activation in vivo, with overlapping organ-system phenotypes between TGF-β1-null and TSP-1-null animals.
• The KRFK activation motif — The activation activity of TSP-1 maps to its three type-1 thrombospondin repeats (TSRs). Within the TSRs, Schultz-Cherry et al. (1995, J Biol Chem; PMID 7706271) identified the four-residue sequence KRFK (Lys-Arg-Phe-Lys), positioned between the first and second type-1 repeats, as the motif responsible for latent-TGF-β activation. A synthetic KRFK tetrapeptide reproduces the activation activity of intact TSP-1 in cell-free and cell-based systems.
• LAP as the docking target — Ribeiro et al. (1999, J Biol Chem; PMID 10224129) mapped the reciprocal binding site on the LAP: the N-terminal LSKL sequence of the latency-associated peptide directly interacts with the TSP-1 KRFK motif. Engagement of LSKL by KRFK disrupts the interaction between LSKL and the RKPK "latency lasso" contact on the mature TGF-β domain, releasing the mature cytokine without any proteolytic cleavage of the complex. A synthetic LSKL peptide competitively blocks TSP-1 / KRFK activation of latent TGF-β, confirming the binding geometry.
• Syn-Coll as a designed KRFK analog (Pal-KVK) — The tripeptide core of Syn-Coll (K-V-K) is pitched as a minimalist mimic of the KRFK activation motif — retaining the two flanking lysine residues (which carry the key basic charge pattern) and substituting valine for the central arginine-phenylalanine dyad. Pentapharm/DSM's mechanistic claim is that Pal-KVK retains the ability to bind the LSKL region of LAP and release active TGF-β, mimicking TSP-1's non-proteolytic activation of the latent complex. This specific claim — that KVK binds LAP with the same disruptive geometry as KRFK — has been asserted by the supplier but has not been independently reproduced in the high-rigor biochemical literature that characterized the native KRFK sequence.
• Downstream TGF-β / SMAD signaling — Whether activated endogenously by TSP-1/KRFK or mimetically by a peptide analog, released active TGF-β engages TGF-β receptor type II (TβRII), which recruits and phosphorylates TGF-β receptor type I (TβRI). The activated receptor complex phosphorylates receptor-regulated SMAD2 and SMAD3, which heterotrimerize with SMAD4 and translocate to the nucleus. The SMAD complex binds SMAD-binding elements in the promoters of matrix genes including COL1A1, COL1A2, COL3A1, and FN1, driving transcription of type I and type III collagen and fibronectin. This is the biochemical route by which TGF-β was first shown to cause "a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts" (Varga, Rosenbloom & Jimenez, 1987, Biochem J; PMID 3501287) — the paper that anchors the entire collagen-signal peptide category.
• Anti-MMP / anti-collagenase claim — Manufacturer technical documentation additionally claims that Syn-Coll modulates matrix metalloproteinases, particularly MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1), thereby reducing degradation of existing dermal collagen alongside the neosynthesis signal. This is mechanistically plausible because activated TGF-β can shift the MMP/TIMP balance in favor of tissue inhibitor of metalloproteinases-1 (TIMP-1), but the specific MMP-modulation claim for Pal-KVK at cosmetic use-levels has not been robustly reproduced in independent literature.
• Palmitoyl moiety — the permeation engineer — The unmodified Lys-Val-Lys tripeptide is hydrophilic, short (MW ≈ 373 Da), and would not meaningfully partition into the stratum corneum's lipid matrix. N-terminal conjugation of palmitic acid (C16 saturated fatty acid) adds a hydrophobic tail that enables partitioning into intercellular lipid lamellae, dramatically increasing skin deposition. This lipo-peptide design — the same strategy used for Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS), palmitoyl tripeptide-1 (Pal-GHK), and palmitoyl tetrapeptide-7 (Pal-GQPR) — is the reason cosmetic signal peptides reach the living epidermis in any clinically meaningful quantity at all.
• What is and is not established — Established: TSP-1 activates latent TGF-β via the KRFK motif binding LAP's LSKL sequence; TGF-β drives collagen I/III/fibronectin mRNA and protein in dermal fibroblasts via SMAD2/3. Not independently established: that a palmitoylated Lys-Val-Lys tripeptide retains sufficient KRFK-like geometry to activate LAP at cosmetic use-levels in living human skin. This is the honest mechanistic frontier for this ingredient.

What the Research Shows

Research on Syn-Coll falls into three tiers: (1) foundational TSP-1 / TGF-β biology, which is high-quality independent peer-reviewed work; (2) in-vitro fibroblast data on palmitoyl tripeptide-5 itself, which is thinner and predominantly supplier-sponsored; and (3) human cosmetic efficacy data for Syn-Coll-containing formulations, which is mostly open-label, split-face, or vehicle-controlled at small sample sizes and generally reported in supplier technical bulletins, cosmetic trade publications, or review articles that cite supplier data.

• Foundational TSP-1 / TGF-β biology (strong) — The Schultz-Cherry / Murphy-Ullrich program (1993–2000) established that TSP-1 non-proteolytically activates latent TGF-β via the KRFK motif binding LAP's LSKL sequence. Crawford et al. (1998, Cell; PMID 9657149) demonstrated physiologic relevance in TSP-1-null mice. This is the biology Syn-Coll is pitched to mimic, and it is real and robust.
• Fibroblast collagen response to TGF-β (strong) — Varga, Rosenbloom & Jimenez (1987, Biochem J; PMID 3501287) established that TGF-β drives a 2–3× enhancement of type I and type III collagen and a 5–8× increase in fibronectin mRNA in cultured normal human dermal fibroblasts, with effects persisting for at least 72 hours after TGF-β removal. This is the cellular-biology foundation for any "stimulate collagen via TGF-β" cosmetic claim, including Syn-Coll's.
• In-vitro Pal-KVK data (thin, predominantly sponsor-originated) — DSM / Pentapharm technical bulletins and derivative trade-journal coverage report that palmitoyl tripeptide-5 upregulates type I collagen synthesis in dermal fibroblast cultures and compares favorably with palmitoyl pentapeptide-4 (Matrixyl) in head-to-head collagen assays. These are not published in indexed peer-reviewed journals as standalone research papers; they appear as supplier claims, conference abstracts, and narrative references within cosmetic-science review articles.
• Human cosmetic efficacy — supplier-sponsored program — A Pentapharm / DSM–sponsored vehicle-controlled clinical assessment commonly cited in trade and review literature tested a Syn-Coll–containing cream against vehicle and against a palmitoyl pentapeptide comparator over an 84-day regimen in approximately 60 healthy female subjects, with PRIMOS 3D surface topography endpoints. The report describes roughly a 3.5× wrinkle-reduction ratio vs placebo and a ~12% reduction in wrinkle-depth parameters. The raw study has not been reproduced in a peer-reviewed independent venue and is cited primarily in supplier documentation and review articles that accept supplier data at face value.
• Narrative cosmetic-science reviews — Lupo & Cole's 2007 Dermatologic Therapy review "Cosmeceutical peptides" (PMID 18045359) — the most widely cited cosmeceutical-peptide review in dermatology — places palmitoyl tripeptide-5 alongside palmitoyl pentapeptide-4 (Matrixyl) and palmitoyl tripeptide-1 in the "signal peptides" category. More recent review articles (Errante et al., 2020, Front Chem, PMC7662462; subsequent cosmetic-science reviews) similarly catalog Syn-Coll among TSP-1-mimicking cosmetic actives without advancing new independent efficacy data.
• Combination/formulation context — Most published evaluations that include palmitoyl tripeptide-5 test it within multi-peptide cosmetic formulations (e.g., alongside Matrixyl 3000, palmitoyl tripeptide-1, Argireline, and antioxidants) rather than as a monotherapy. This makes any observed efficacy attributable to the ensemble rather than to Syn-Coll specifically and is the main reason independent isolation of Syn-Coll's effect size is difficult.
• No human wrinkle-morphometry RCT in PubMed — A direct PubMed search for "palmitoyl tripeptide-5" as a monotherapy in a vehicle-controlled randomized wrinkle-endpoint trial returns supplier and review coverage but not a standalone peer-reviewed RCT at the rigor level one would expect for a topical retinoid or niacinamide study. This is the single most important evidence-quality caveat for this compound.

Human Data

Human data on Syn-Coll is limited to cosmetic efficacy and tolerance studies — there are no clinical trials of systemic palmitoyl tripeptide-5, because the compound is a topical ingredient by design and no regulatory authority has ever approved or investigated it for systemic use. Specific human-subject evaluations that appear in the literature and supplier documentation:

• Pentapharm / DSM Syn-Coll sponsor study (≈60 subjects, 84 days) — Vehicle-controlled evaluation of a topical formulation containing Syn-Coll against vehicle placebo and against a palmitoyl pentapeptide (Matrixyl-class) comparator cream. PRIMOS 3D optical topography was used to quantify periorbital wrinkle depth and roughness parameters. Reported outcomes: approximately 3.5× wrinkle-parameter improvement vs vehicle and a ~12% reduction in aggregate wrinkle-depth score over 84 days, favoring Syn-Coll over comparator. Study report is primarily available in DSM's Syn-Coll technical bulletin and cited secondarily in cosmetic-science review articles (e.g., Lupo & Cole 2007; more recent DSM product-literature updates). Not indexed as an independent peer-reviewed randomized trial in PubMed.
• Multi-peptide formulation trials — Several independent cosmetic efficacy studies evaluating multi-active formulations that include palmitoyl tripeptide-5 alongside palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, and/or acetyl hexapeptide-8 (Argireline). These report modest but statistically measurable reductions in wrinkle-depth, improvements in dermal density on ultrasound imaging, and improved subject self-assessment. Because the formulations contain multiple actives, these studies do not isolate Syn-Coll's contribution.
• Tolerance and patch-test data — Supplier safety documentation reports good tolerance of finished formulations containing 2–4% Syn-Coll solution in 48-hour patch tests and 21-day cumulative irritation studies, with irritation scores indistinguishable from vehicle at normal cosmetic concentrations. Independent replication is limited but consistent with the general experience that short synthetic lipopeptides at micromolar use-levels are well tolerated topically.
• Sensitization risk — The Cosmetic Ingredient Review (CIR) Expert Panel has evaluated the broader palmitoyl-peptide class and concluded that available data do not indicate a meaningful risk of contact sensitization at current cosmetic use concentrations, though the Panel routinely notes that formal repeat-insult patch test (RIPT) and human maximization test data for each individual peptide in this class are limited.
• What is not in the human evidence base — No randomized placebo-controlled monotherapy trial of palmitoyl tripeptide-5 with pre-registered primary wrinkle-morphometry endpoints published in a PubMed-indexed dermatology journal. No histological biopsy studies demonstrating measurable collagen-density change in biopsied skin sections after topical Syn-Coll application. No comparative effectiveness data against topical tretinoin, retinol, or a well-characterized growth-factor serum.

The honest read is that Syn-Coll has been used in finished cosmetic products and tolerated safely by large numbers of consumers for roughly two decades, which is real-world evidence of safety at cosmetic use-levels. Its efficacy as an isolated active is supported by mechanistically coherent supplier-sponsored data and by the robustness of the upstream TSP-1/TGF-β biology, but not by the kind of independent randomized trial portfolio one would expect for a drug candidate.

Dosing from the Literature

Syn-Coll "dosing" is a formulation parameter, not a clinical dose. Supplier documentation and the cosmetic-science literature converge on the following use levels:

The cosmetic regimen described in the Pentapharm sponsor study — twice-daily application of a 2.5% Syn-Coll–containing cream over 84 days — is the most commonly cited "dose" in the trade and review literature. Effects on visible wrinkle parameters in the sponsor data manifested over 28 days (early trend) to 84 days (fuller effect), consistent with the general time course of dermal matrix remodeling under a chronic signal.

Reconstitution & Storage

Syn-Coll is supplied by DSM and by cosmetic-ingredient distributors as a ready-to-use aqueous solution, typically preservative-free and designed to be added to the aqueous phase of a cosmetic formulation. There is no reconstitution step analogous to injectable peptides. Formulator-relevant handling details:

In practical cosmetic formulation, Syn-Coll is added after the emulsion has cooled below 40°C to prevent thermal degradation of the peptide bond. It is compatible with the vast majority of common cosmetic bases (emulsions, gels, serums) and can be co-formulated with other signal peptides, hyaluronic acid, niacinamide, panthenol, and most antioxidants. Avoid co-formulation with strong oxidizers, high concentrations of free-radical–generating ingredients, and extreme pH shifts.

→ Use the Kalios Dosing Calculator for research-reference comparisons (topical use only — no injection route supported)

Side Effects & Risks

At properly formulated cosmetic use-levels in finished products, Syn-Coll is generally well tolerated. Its risk profile is characteristic of short synthetic lipopeptides in topical cosmetics. Key considerations:

• Local skin reactions — uncommon — Transient erythema, mild stinging, or localized irritation can occur, particularly in sensitive or compromised skin. Most reactions in this ingredient class are attributable to other formulation components (preservatives, fragrances, surfactants) rather than to the peptide itself.
• Contact sensitization — low incidence — Formal sensitization reports specific to palmitoyl tripeptide-5 are rare. The Cosmetic Ingredient Review panel has not identified palmitoyl-peptide sensitization as a category-level concern at cosmetic use levels.
• Use on broken or compromised skin — Not intended for application to open wounds, active dermatitis, eroded skin, or post-procedure skin in the first 24–48 hours. Increased penetration into live tissue in those conditions could deliver unpredictable concentrations of a TGF-β–activating signal to wound-bed fibroblasts and myofibroblasts.
• Theoretical concern — chronic topical TGF-β activation — Sustained TGF-β activation in skin fibroblasts is mechanistically linked to fibrotic processes including hypertrophic scar, keloid formation, and scleroderma. The cosmetic dose of Pal-KVK is several orders of magnitude below anything that would be expected to drive pathological fibrosis, and decades of cosmetic use have not generated a fibrotic-risk signal in post-market surveillance. Still, patients with known keloid-prone skin, active hypertrophic scarring, or systemic sclerosis should consider the theoretical TGF-β-pathway activation when choosing active ingredients.
• Pregnancy and lactation — No specific safety data on topical palmitoyl tripeptide-5 in pregnant or lactating women. General cosmetic-use guidance for pregnancy recommends minimizing exposure to novel actives without pregnancy-specific safety data. Fragrance-free, well-established products are the conservative default during pregnancy.
• Interaction with retinoids and AHAs — No specific pharmacological interaction has been characterized, but layering a TGF-β–signal peptide with retinoids and alpha-hydroxy acids may increase overall skin stimulation. A conservative approach alternates nights (retinoid one night, peptide the next) in sensitive users.
• Sunscreen still required — No topical peptide substitutes for broad-spectrum UVA/UVB sunscreen. Sunscreen remains the single highest-evidence topical intervention for photoaging.
• Not for injection — There are no safety studies supporting subcutaneous, intramuscular, intravenous, intradermal, or mesotherapy injection of palmitoyl tripeptide-5. Injection of a cosmetic-grade ingredient bypasses the intended safety evaluation pathway and can introduce endotoxin, preservative, and sterility risks that do not apply to topical application. Do not inject Syn-Coll.
• Do not ingest — No oral safety or bioavailability data. Peptide bonds would be cleaved by gastric and pancreatic proteases; there is no plausible oral route of action for a cosmetic signal peptide.
• Ocular exposure — Avoid direct ocular contact. Peri-ocular application in eye-cream formulations is intended; the eye itself is not.

Bloodwork & Monitoring

Routine clinical bloodwork or laboratory monitoring is not indicated for topical use of Syn-Coll in a finished cosmetic product. Topical palmitoyl tripeptide-5 does not reach systemic circulation at measurable concentrations from standard cosmetic application, and there is no signal in cosmetic pharmacovigilance that would warrant laboratory surveillance. For context:

• Systemic absorption — negligible — Small lipopeptides at 20–80 ppm applied to intact stratum corneum show limited penetration to the dermal capillary bed; systemic concentrations after normal cosmetic use are not clinically relevant. No routine serum monitoring is warranted.
• Liver / kidney panels — Not indicated. There is no hepatotoxic or nephrotoxic signal associated with topical palmitoyl tripeptide-5.
• Inflammatory markers / cytokines — Not indicated for cosmetic use. Research-context TGF-β, CRP, or IL-6 monitoring would only be relevant in a formal investigational dermatology trial, which is not the use context for this ingredient.
• Skin-level monitoring (formulation trials only) — In formal cosmetic efficacy trials, endpoint measurements typically include PRIMOS 3D optical topography for wrinkle depth/density, cutometer measurements for skin elasticity, corneometer measurements for stratum corneum hydration, trans-epidermal water loss (TEWL) via evaporimeter, and standardized photography. These are study-specific and not part of consumer or clinical monitoring.
• Patch testing — sensitive or reactive users — For users with a history of contact dermatitis or reactive skin, a small-area patch test of any new peptide-containing formulation over 48–72 hours before full-face use is a conservative precaution.
• If unusual systemic symptoms occur — Attribute first to other formulation components (fragrance, preservatives, emulsifiers, essential oils) and to concurrent topical actives, then consider full discontinuation and consultation with a dermatologist.

Syn-Coll is, for practical purposes, a low-clinical-footprint cosmetic ingredient — the monitoring relevant to its use is standard cosmetic-tolerance observation, not systemic laboratory surveillance.

Commonly Stacked With

Syn-Coll is almost never used as a solo active in contemporary cosmetic formulation. Signal peptides act on a small fraction of dermal matrix biology each, and formulators routinely layer mechanistically complementary peptides for additive effect. Common topical pairings:

→ Check compound compatibility in the Stack Builder (research-reference comparisons; Syn-Coll is topical only)

Regulatory Status

Related Compounds

Cosmetic signal peptides in the same collagen-signaling class:

Next Steps

Key References

1. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993;122(4):923-932. doi:10.1083/jcb.122.4.923. PMID: 8349738. (The foundational paper demonstrating non-proteolytic TSP-1 activation of latent TGF-β — the parent mechanism Syn-Coll is designed to mimic.)
2. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994;269(43):26775-26782. PMID: 7929413.
3. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem. 1994;269(43):26783-26788. PMID: 7929414.
4. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem. 1995;270(13):7304-7310. doi:10.1074/jbc.270.13.7304. PMID: 7706271. (Localization of the KRFK activation motif — the native sequence Pal-KVK is designed to mimic.)
5. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159-1170. doi:10.1016/s0092-8674(00)81460-9. PMID: 9657149. (Genetic demonstration in TSP-1-null mice that the TSP-1 → TGF-β activation axis is physiologically required in vivo.)
6. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem. 1999;274(19):13586-13593. doi:10.1074/jbc.274.19.13586. PMID: 10224129. (Mapping of the reciprocal LAP–LSKL / TSP-1–KRFK binding interaction.)
7. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1-2):59-69. doi:10.1016/s1359-6101(99)00029-5. PMID: 10708953. (Definitive mechanistic review of TSP-1-dependent TGF-β activation.)
8. Murphy-Ullrich JE, Schultz-Cherry S, Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell. 1992;3(2):181-188. doi:10.1091/mbc.3.2.181. (Original biochemical characterization of the TSP-1 / TGF-β complex.)
9. Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease. Matrix Biol. 2018;68-69:28-43. doi:10.1016/j.matbio.2017.12.009. (Comprehensive modern review of TSP-1 / TGF-β targeting for disease; PMC6015530.)
10. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247(3):597-604. doi:10.1042/bj2470597. PMID: 3501287. (The foundational dermal-fibroblast paper demonstrating TGF-β drives sustained collagen I / III and fibronectin mRNA upregulation — the downstream effect all TGF-β–mimetic cosmetic peptides invoke.)
11. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261(9):4337-4345. PMID: 3456347. (Early demonstration of TGF-β–driven matrix gene expression; co-foundational to Varga 1987.)
12. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (The most widely cited dermatology review of cosmeceutical peptides; positions palmitoyl tripeptide-5 within the signal-peptide class.)
13. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. doi:10.3389/fchem.2020.572923. PMC7662462. (Modern cosmetic-science review cataloging Syn-Coll among TSP-1–mimicking cosmetic actives.)
14. Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416, v. doi:10.1016/j.det.2009.05.006. PMID: 19850190. (Dermatology practice-level overview of cosmeceutical peptide use, including TGF-β–mimetic tripeptides.)
15. Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem. 2004;279(36):38032-38039. doi:10.1074/jbc.M405658200. PMID: 15208302. (Biochemical characterization of the LAP "latency lasso" that TSP-1 KRFK disrupts.)
16. Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem. 2004;279(46):47633-47642. doi:10.1074/jbc.M404918200. PMID: 15347654. (Identification of the WxxW "docking" motif that orients KRFK on LAP.)
17. Pentapharm / DSM Nutritional Products. Syn®-Coll technical data sheet and efficacy dossier (product literature). DSM Personal Care, Basel, Switzerland. (Supplier-originated dossier describing Syn-Coll's in-vitro collagen upregulation data and the 84-day sponsor-run human wrinkle-morphometry study referenced throughout the cosmetic-science review literature. Not indexed in PubMed.)
18. Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides and Palmitoyl Polypeptides as Used in Cosmetics. Int J Toxicol. CIR Final Report (periodic updates). (Regulatory safety review of the palmitoyl-peptide class, including palmitoyl tripeptide-5.)